Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 6/2017

01-11-2017 | Original Article

Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease

Authors: Marie-Thérèse Abi-Wardé, Célina Roda, Jean-Baptiste Arnoux, Aude Servais, Florence Habarou, Anais Brassier, Clément Pontoizeau, Valérie Barbier, Manuella Bayart, Virginie Leboeuf, Bernadette Chadefaux-Vekemans, Sandrine Dubois, Murielle Assoun, Claire Belloche, Jean-Meidi Alili, Marie-Caroline Husson, Fabrice Lesage, Laurent Dupic, Benoit Theuil, Chris Ottolenghi, Pascale de Lonlay

Published in: Journal of Inherited Metabolic Disease | Issue 6/2017

Login to get access

Abstract

Background

Maple syrup urine disease (MSUD) is a rare disease that requires a protein-restricted diet for successful management. Little is known, however, about the psychosocial outcome of MSUD patients. This study investigates the relationship between metabolic and clinical parameters and psychosocial outcomes in a cohort of patients with neonatal-onset MSUD.

Methods

Data on academic achievement, psychological care, family involvement, and biochemical parameters were collected from the medical records of neonatal MSUD patients treated at Necker Hospital (Paris) between 1964 and 2013.

Results

Thirty-five MSUD patients with a mean age of 16.3 (2.1–49.0) years participated. Metabolic decompensations (plasma leucine >380 μmol/L) were more frequent during the first year of life and after 15 years, mainly due to infection and dietary noncompliance, respectively. Leucine levels increased significantly in adulthood: 61.5% of adults were independent and achieved adequate social and professional integration; 56% needed occasional or sustained psychological or psychiatric care (8/19, with externalizing, mood, emotional, and anxiety disorders being the most common). Patients needing psychiatric care were significantly older [mean and standard deviation (SD) 22.6 (7.7) years] than patients needing only psychological follow-up [mean (SD) 14.3 (8.9) years]. Patients with psychological follow-up experienced the highest lifetime number of decompensations; 45% of families had difficulty coping with the chronic disease. Parental involvement was negatively associated with the number of lifetime decompensations.

Conclusion

Adults had increased levels of plasma leucine, consistent with greater chronic toxicity. Psychological care was associated with age and number of decompensations. In addition, parental involvement appeared to be crucial in the management of MSUD patients.
Literature
go back to reference Aoki K, Wada Y (1988) Outcome of the patients detected by newborn screening in Japan. Acta Paediatr Jpn Overseas Ed 30:429–434CrossRef Aoki K, Wada Y (1988) Outcome of the patients detected by newborn screening in Japan. Acta Paediatr Jpn Overseas Ed 30:429–434CrossRef
go back to reference Clow CL, Reade TM, Scriver CR (1981) Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics 68:856–862PubMed Clow CL, Reade TM, Scriver CR (1981) Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics 68:856–862PubMed
go back to reference Haroon E, Fleischer CC, Felger JC et al (2016) Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry 21(10):1351–1357 Haroon E, Fleischer CC, Felger JC et al (2016) Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry 21(10):1351–1357
go back to reference Hilliges C, Awiszus D, Wendel U (1993) Intellectual performance of children with maple syrup urine disease. Eur J Pediatr 152:144–147CrossRefPubMed Hilliges C, Awiszus D, Wendel U (1993) Intellectual performance of children with maple syrup urine disease. Eur J Pediatr 152:144–147CrossRefPubMed
go back to reference Ibarra-González I, Fernández-Lainez C, Belmont-Martínez L, Vela-Amieva M (2007) Increased mortality and disability in a cohort of Mexican children with maple syrup urine disease. Gac Med Mex 143:197–201PubMed Ibarra-González I, Fernández-Lainez C, Belmont-Martínez L, Vela-Amieva M (2007) Increased mortality and disability in a cohort of Mexican children with maple syrup urine disease. Gac Med Mex 143:197–201PubMed
go back to reference Kowalik A, Narojek L, Sykut-Cegielska J (2007) Compliance of the diet restricted with leucine, isoleucine and valine in maple syrup urine disease (MSUD) children. Rocz Państw Zakł Hig 58:95–101PubMed Kowalik A, Narojek L, Sykut-Cegielska J (2007) Compliance of the diet restricted with leucine, isoleucine and valine in maple syrup urine disease (MSUD) children. Rocz Państw Zakł Hig 58:95–101PubMed
go back to reference Morton DH, Strauss KA, Robinson DL et al (2002) Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 109:999–1008CrossRefPubMed Morton DH, Strauss KA, Robinson DL et al (2002) Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 109:999–1008CrossRefPubMed
go back to reference Sgaravatti AM, Rosa RB, Schuck PF et al (2003) Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 1639:232–238CrossRefPubMed Sgaravatti AM, Rosa RB, Schuck PF et al (2003) Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 1639:232–238CrossRefPubMed
go back to reference Simon E, Wendel U, Schadewaldt P (2005) Maple syrup urine disease-treatment and outcome in patients of Turkish descent in Germany. Turk J Pediatr 47:8–13PubMed Simon E, Wendel U, Schadewaldt P (2005) Maple syrup urine disease-treatment and outcome in patients of Turkish descent in Germany. Turk J Pediatr 47:8–13PubMed
go back to reference Strauss KA, Morton DH (2003) Branched-chain Ketoacyl Dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol 5:329–341CrossRefPubMed Strauss KA, Morton DH (2003) Branched-chain Ketoacyl Dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol 5:329–341CrossRefPubMed
go back to reference Weber SL, Segal S, Packman W (2012) Inborn errors of metabolism: psychosocial challenges and proposed family systems model of intervention. Mol Genet Metab 105:537–541CrossRefPubMed Weber SL, Segal S, Packman W (2012) Inborn errors of metabolism: psychosocial challenges and proposed family systems model of intervention. Mol Genet Metab 105:537–541CrossRefPubMed
go back to reference Yoshino M, Aoki K, Akeda H et al (1999) Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study. Pediatr Int 41:132–137CrossRefPubMed Yoshino M, Aoki K, Akeda H et al (1999) Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study. Pediatr Int 41:132–137CrossRefPubMed
go back to reference Yudkoff M, Daikhin Y, Nissim I et al (2005) Brain amino acid requirements and toxicity: the example of leucine. J Nutr 135:1531S–1538SPubMed Yudkoff M, Daikhin Y, Nissim I et al (2005) Brain amino acid requirements and toxicity: the example of leucine. J Nutr 135:1531S–1538SPubMed
Metadata
Title
Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease
Authors
Marie-Thérèse Abi-Wardé
Célina Roda
Jean-Baptiste Arnoux
Aude Servais
Florence Habarou
Anais Brassier
Clément Pontoizeau
Valérie Barbier
Manuella Bayart
Virginie Leboeuf
Bernadette Chadefaux-Vekemans
Sandrine Dubois
Murielle Assoun
Claire Belloche
Jean-Meidi Alili
Marie-Caroline Husson
Fabrice Lesage
Laurent Dupic
Benoit Theuil
Chris Ottolenghi
Pascale de Lonlay
Publication date
01-11-2017
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 6/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0083-x

Other articles of this Issue 6/2017

Journal of Inherited Metabolic Disease 6/2017 Go to the issue

Highlights

News and views

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.